Clinical Trials Logo

Clinical Trial Summary

Gallium-68-DOTATOC binds primarily with high affinity to somatostatin subtype 2 (SSTR2) receptors and these somatostatin receptors are also overexpressed on inflammation cells when activated. The hypothesis is that the GATED mode on a Gallium-68-DOTATOC cardiac recording would be able to highlight abnormalities that could be correlated with the age of the patients and their cardiovascular risk factors.


Clinical Trial Description

People with the selection criteria for the study, coming to the nuclear medicine department in order to benefit from a Gallium-68-DOTATOC PET/CT exam as part of a diagnostic or pre-therapeutic assessment of a neuroendocrine tumor will be offer to participate in the study After sign consent, patients were install in a room to have blood drawn for Troponin Ic, BNP and CRP and after Gallium-68-DOTATOC infusion Gallium-68-DOTATOC PET/CT will be recorded and immediately the cardiac record in Gated mode ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06467968
Study type Interventional
Source Central Hospital, Nancy, France
Contact VERONIQUE ROCH, MSc
Phone 03 83 15 42 76
Email v.roch@chru-nancy.fr
Status Recruiting
Phase N/A
Start date February 2, 2023
Completion date August 26, 2025

See also
  Status Clinical Trial Phase
Completed NCT05328713 - Immune Correlates of Cardiac Structure and Function
Active, not recruiting NCT01046604 - Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery Phase 4